GUARDANT ABCT 10 Wait. An accurate blood test? For colorectal cancer (CRC) screening?¹ NO WAY! The Shield test can help you overcome CRC screening adherence challenges² NOW FDA APPROVED shield Validated by the ECLIPSE study, published in the New England Journal of Medicine¹ ECLIPSE established the Shield test's ability to accurately detect CRC and enrolled over 20,000 patients.*+ 83% Overall CRC sensitivity Simplified screening that is accessible and easy to complete 1118 90% Of the first 20,000 patients offered the Shield LDT, 9 out of 10 patients Specificity completed screening with Shield³ shield Start screening with the Shield blood test *Patients had no prior diagnosis of CRC, inflammatory bowel disease, or hereditary predisposition to CRC (eg, Lynch syndrome). The clinical validation cohort included over 10,000 patients. 7861 patients were included in the final clinical validation cohort. #Internal data on file, March 2024. Data from real-world clinical settings. Data based on Laboratory Developed Test (LDT) usage of Shield, which has not been cleared or approved by the FDA. Important Safety Information Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stage II, III, and IV colorectal cancer. GUARDANT ABCT 10 Wait . An accurate blood test ? For colorectal cancer ( CRC ) screening ? ¹ NO WAY ! The Shield test can help you overcome CRC screening adherence challenges² NOW FDA APPROVED shield Validated by the ECLIPSE study , published in the New England Journal of Medicine¹ ECLIPSE established the Shield test's ability to accurately detect CRC and enrolled over 20,000 patients . * + 83 % Overall CRC sensitivity Simplified screening that is accessible and easy to complete 1118 90 % Of the first 20,000 patients offered the Shield LDT , 9 out of 10 patients Specificity completed screening with Shield³ shield Start screening with the Shield blood test * Patients had no prior diagnosis of CRC , inflammatory bowel disease , or hereditary predisposition to CRC ( eg , Lynch syndrome ) . The clinical validation cohort included over 10,000 patients . 7861 patients were included in the final clinical validation cohort . #Internal data on file , March 2024. Data from real - world clinical settings . Data based on Laboratory Developed Test ( LDT ) usage of Shield , which has not been cleared or approved by the FDA . Important Safety Information Precaution : Based on data from clinical studies , Shield has limited detection ( 55 % -65 % ) of Stage I colorectal cancer and does not detect 87 % of precancerous lesions . One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy . Shield demonstrated high detection of Stage II , III , and IV colorectal cancer .